Axon Enterprise, Inc. (NASDAQ:AXON) Director Jeri Williams Sells 307 Shares

Axon Enterprise, Inc. (NASDAQ:AXON) Director Jeri Williams sold 307 shares of the business’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $552.72, for a total transaction of $169,685.04. Following the completion of the transaction, the director now owns 1,627 shares of the company’s stock, valued at approximately $899,275.44. This trade represents a 15.87 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Axon Enterprise Stock Performance

AXON traded down $14.83 on Tuesday, reaching $539.99. The company had a trading volume of 558,304 shares, compared to its average volume of 857,660. Axon Enterprise, Inc. has a 1 year low of $273.52 and a 1 year high of $715.99. The stock has a market capitalization of $41.38 billion, a PE ratio of 139.53, a P/E/G ratio of 5.17 and a beta of 1.12. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The stock has a 50-day moving average price of $592.66 and a 200-day moving average price of $539.27.

Institutional Investors Weigh In On Axon Enterprise

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. 111 Capital purchased a new stake in Axon Enterprise in the fourth quarter valued at $280,000. Wealth Enhancement Advisory Services LLC lifted its position in Axon Enterprise by 36.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,932 shares of the biotechnology company’s stock valued at $10,063,000 after acquiring an additional 4,510 shares during the last quarter. Lansforsakringar Fondforvaltning AB publ purchased a new stake in Axon Enterprise in the fourth quarter valued at $13,986,000. Centaurus Financial Inc. lifted its position in Axon Enterprise by 43.9% in the fourth quarter. Centaurus Financial Inc. now owns 6,517 shares of the biotechnology company’s stock valued at $3,873,000 after acquiring an additional 1,989 shares during the last quarter. Finally, Wealthedge Investment Advisors LLC purchased a new stake in Axon Enterprise in the fourth quarter valued at $1,677,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Northcoast Research downgraded shares of Axon Enterprise from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 19th. Barclays restated a “hold” rating on shares of Axon Enterprise in a research note on Monday, March 10th. Robert W. Baird boosted their price target on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research note on Friday, December 6th. Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $500.00 to $700.00 in a research note on Tuesday, December 3rd. Finally, JMP Securities restated an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $604.67.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.